AB AB Science S.A.

Etude de l'AG du 15/12/2017

La présente assemblée vise à modifier les caractéristiques de plans d'actions de prérences ("Actions B") (résolution 2) et ceux de plans passés de bons de souscription ("BCE") et de bons de souscription d'actions ("BSA") (résolution 3 et 4). Ces plans posent à la fois des problèmes de dilution (l'ensemble des plans représente une dilution de plus de 10% du capital de la société), de plafonnement (pas de plafonnement pour les dirigeants), et parfois d'alignement avec la performance. Par conséquent, nous ne pouvons approuver aucune de ces trois résolutions.

La résolution propose également la nomination de Nathalie Ruez, une nouvelle administratrice indépendante (résolution 1), ce qui permet à la société d'être en ligne avec la loi Copé-Zimmermann, et qui renforce son taux d'indépendance (qui atteindra 40% à l'issue de la prochaine assemblée). Par conséquent, nous approuvons cette nomination.

03/12/2017
12 pages
FR

Research Provider

Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.

Proxinvest main services are :

  • ​Proxy reports
  • Definition and monitoring of client customized voting guidelines
  • Corporate Governance Data and Rating
  • Thematic research
  • Engagement support

Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.

Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.

As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide. 

Read more

Underlying

Health Care - France

AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signaling patways within cells. Co. targets diseases such as cancer, inflammatory diseases and central nervous system diseases, in both human and veterinary medecines. Co. has developed its own portfolio of molecules including masitinib, which has already been registered in Europe and the U.S.A. and is pursuing five phase 3 studies in human medecine, including studies in pancreatic cancer, GIST, metastatic melanoma, and studies in mastocytosis and severe persistent asthma.

Read more

ResearchPool Subscriptions

Get the most out of your insights

Get in touch